Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076186 · ClinicalTrials.gov registry record · Phase 2
Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS
A Phase 2 study of Uterine Leiomyosarcoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT07076186 is a Phase 2 study of Uterine Leiomyosarcoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants, above the 34-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (41% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07076186, a Phase 2 study of Uterine Leiomyosarcoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
To find out if receiving standard chemotherapy (doxorubicin and trabectedin) can extend the cancer-free survival of patients with Stage 1b/2 uterine leiomyosarcoma who had surgery that fully removed the tumor.
Conditions Studied
Interventions
- DRUG Doxorubicin Hydrochloride
- DRUG Trabectedin
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2029-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07076186
The ClinicalTrials.gov registry entry for NCT07076186 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 34-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (41% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uterine Leiomyosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Doxorubicin Hydrochloride is the first listed.
NCT07076186 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07076186 about?
NCT07076186 is a clinical study titled "Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS". To find out if receiving standard chemotherapy (doxorubicin and trabectedin) can extend the cancer-free survival of patients with Stage 1b/2 uterine leiomyosarcoma who had surgery that fully removed the tumor.
What is the current status of trial NCT07076186?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2025-10-02. Estimated completion is 2029-12-02.
What conditions does trial NCT07076186 study?
This clinical trial studies the following conditions: Uterine Leiomyosarcoma.
What interventions are being tested in trial NCT07076186?
The interventions under investigation include: Doxorubicin Hydrochloride (DRUG), Trabectedin (DRUG).
Who is sponsoring clinical trial NCT07076186?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076186 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.